Cargando…
Immuno(T)herapy for age‐related diseases
During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients sufferi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832825/ https://www.ncbi.nlm.nih.gov/pubmed/36373340 http://dx.doi.org/10.15252/emmm.202216301 |
_version_ | 1784868134110363648 |
---|---|
author | Gabandé‐Rodríguez, Enrique Pfeiffer, Matilda Mittelbrunn, María |
author_facet | Gabandé‐Rodríguez, Enrique Pfeiffer, Matilda Mittelbrunn, María |
author_sort | Gabandé‐Rodríguez, Enrique |
collection | PubMed |
description | During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients suffering from oncological processes, especially those affected by hematological neoplasms. Recent evidence suggest that the use of immunotherapy could be extended to non‐oncological diseases and could be especially relevant for age‐associated disorders, opening exciting therapeutic options for a wide range of diseases of the elderly. Here we comment on the emergence of T‐cell‐based immunotherapies as feasible approaches that could revolutionize the future of GeroScience. |
format | Online Article Text |
id | pubmed-9832825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98328252023-01-12 Immuno(T)herapy for age‐related diseases Gabandé‐Rodríguez, Enrique Pfeiffer, Matilda Mittelbrunn, María EMBO Mol Med Commentary During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients suffering from oncological processes, especially those affected by hematological neoplasms. Recent evidence suggest that the use of immunotherapy could be extended to non‐oncological diseases and could be especially relevant for age‐associated disorders, opening exciting therapeutic options for a wide range of diseases of the elderly. Here we comment on the emergence of T‐cell‐based immunotherapies as feasible approaches that could revolutionize the future of GeroScience. John Wiley and Sons Inc. 2022-11-14 /pmc/articles/PMC9832825/ /pubmed/36373340 http://dx.doi.org/10.15252/emmm.202216301 Text en © 2022 The Authors. Published under the terms of the CC BY 4.0 license. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Gabandé‐Rodríguez, Enrique Pfeiffer, Matilda Mittelbrunn, María Immuno(T)herapy for age‐related diseases |
title | Immuno(T)herapy for age‐related diseases |
title_full | Immuno(T)herapy for age‐related diseases |
title_fullStr | Immuno(T)herapy for age‐related diseases |
title_full_unstemmed | Immuno(T)herapy for age‐related diseases |
title_short | Immuno(T)herapy for age‐related diseases |
title_sort | immuno(t)herapy for age‐related diseases |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832825/ https://www.ncbi.nlm.nih.gov/pubmed/36373340 http://dx.doi.org/10.15252/emmm.202216301 |
work_keys_str_mv | AT gabanderodriguezenrique immunotherapyforagerelateddiseases AT pfeiffermatilda immunotherapyforagerelateddiseases AT mittelbrunnmaria immunotherapyforagerelateddiseases |